AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21839707 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination diet (without cow's milk and derivatives, wheat, egg, tomato, and chocolate) for 4 weeks
Number of subjects: 160
Study 21839707 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal ECP assay
Number of subjects: 160
Study 21839707 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal tryptase assay
Number of subjects: 160
Study 19619148 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox (20 I.E. diluted in 0.5 mL saline)
Number of subjects: 64
Study 19619148 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.5 mL saline)
Number of subjects: 64
Study 17784794 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiments with student attrition
Number of subjects: 35
Study 17784794 — intervention group
Group type: COMPARATOR
Intervention: Experiments without student attrition
Number of subjects: 35
Study 17784794 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall attrition rates
Number of subjects: 35
Study 17784794 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential attrition rates
Number of subjects: 35
Study 15005715 — intervention group
Group type: EXPERIMENTAL
Intervention: C516T 5HT2A gene polymorphism
Number of subjects: 79
Study 15005715 — intervention group
Group type: COMPARATOR
Intervention: COMT gene polymorphisms
Number of subjects: 79
Study 15005715 — intervention group
Group type: COMPARATOR
Intervention: 5HTTLPR gene polymorphisms
Number of subjects: 79
Study 15005715 — intervention group
Group type: COMPARATOR
Intervention: T102C 5HT2A gene polymorphisms
Number of subjects: 79
Study 11437759 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 40
Study 11437759 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40
Study 9579877 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse antilymphocyte globulin (HALG)
Number of subjects: 0
Study 9579877 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (RATG)
Number of subjects: 0
Study 9579877 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytohaemagglutinin (PHA)
Number of subjects: 0
Study 9579877 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell supernatants with recombinant human GM-CSF (rhGM-CSF)
Number of subjects: 0
Study 9579877 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell supernatants without growth factor
Number of subjects: 0
Study 7921346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alcohol infusion (0.5 g ethanol per kg body weight in 15 minutes)
Number of subjects: 12
Study 2662037 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g elemental calcium for 5 days)
Number of subjects: 18
Study 2662037 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 18
Study 31960275 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (250 mg magnesium oxide) for 8 weeks
Number of subjects: 60
Study 31722151 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartwatch-based irregular pulse notification algorithm
Number of subjects: 419297
Study 27995531 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous IFN‐β‐1a 44 mcg three times a week (group 1)
Number of subjects: 0
Study 27995531 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous IFN‐β‐1a 44 mcg three times a week plus ethinyl estradiol 40 mcg and desogestrel 125 mcg (group 3)
Number of subjects: 0
Study 27995531 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous IFN‐β‐1a 44 mcg three times a week plus ethinyl estradiol 20 mcg and desogestrel 150 mcg (group 2)
Number of subjects: 0
Study 25496007 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclabuvir 75 mg plus pegIFN (180 μg) and RBV (1000 mg/day [<75 kg])
Number of subjects: 39
Study 25496007 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclabuvir 150 mg plus pegIFN (180 μg) and RBV (1200 mg/day [≥ 75 kg])
Number of subjects: 39
Study 25496007 — intervention group
Group type: COMPARATOR
Intervention: PegIFN/RBV alone
Number of subjects: 39
Study 23979614 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (25 microgram every six hours for a Bishop score lower than 7)
Number of subjects: 101
Study 23979614 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin (low dose regimen for a Bishop score equal to or more than 7)
Number of subjects: 101
Study 23979614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical ripening factors
Number of subjects: 101
Study 23979614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical posterior angle
Number of subjects: 101
Study 23979614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length, Body Mass Index (BMI), and parity
Number of subjects: 101
Study 20977367 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival bevacizumab (7.5 mg total: 5 mg/0.2 mL on the day of surgery and 2.5 mg on the fourth day after surgery)
Number of subjects: 44
Study 20977367 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (0.2 mL at the end of surgery)
Number of subjects: 44
Study 19242918 — intervention group
Group type: COMPARATOR
Intervention: 6-month, home-based exercise program (n=25)
Number of subjects: 125
Study 19242918 — intervention group
Group type: COMPARATOR
Intervention: 6-month, supervised exercise intervention (n=37)
Number of subjects: 125
Study 19242918 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=25) for newly diagnosed survivors
Number of subjects: 125
Study 19242918 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=38) for post-treatment survivors
Number of subjects: 125
Study 16739538 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia tutorial
Number of subjects: 174
Study 16739538 — intervention group
Group type: COMPARATOR
Intervention: Control group (took the tutorial before posttest)
Number of subjects: 174
Study 15315114 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized formulas in long duration patients
Number of subjects: 511
Study 15315114 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized formulas in kidney failure patients
Number of subjects: 511
Study 15315114 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized formulas in liver failure patients
Number of subjects: 511
Study 11264207 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise programme delivered by trained nurses
Number of subjects: 450
Study 11264207 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 450
Study 9706364 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referred genetic counseling for breast-ovarian cancer risk
Number of subjects: 256
Study 8586330 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (group A)
Number of subjects: 80
Study 8586330 — intervention group
Group type: COMPARATOR
Intervention: Brachial plexus analgesia (group K)
Number of subjects: 80
Study 2680140 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 5356
Study 2680140 — intervention group
Group type: COMPARATOR
Intervention: Saline inoculations (Control)
Number of subjects: 5356
Study 810719 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 40
Study 810719 — intervention group
Group type: COMPARATOR
Intervention: Surgical therapy (urgent surgical coronary bypass)
Number of subjects: 40
Study 810719 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy and Surgical therapy
Number of subjects: 40
Study 31005973 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation (20 g daily for 4 weeks)
Number of subjects: 12
Study 31005973 — intervention group
Group type: COMPARATOR
Intervention: Low-BCAA control (protein low in BCAAs for 4 weeks)
Number of subjects: 12
Study 31005973 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 12
Study 31005973 — intervention group
Group type: COMPARATOR
Intervention: Low-BCAA control
Number of subjects: 12
Study 28891830 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive fluid infusion (5 mL/kg/h lactated Ringer solution)
Number of subjects: 100
Study 28891830 — intervention group
Group type: COMPARATOR
Intervention: Liberal fluid infusion (30 mL/kg/h lactated Ringer solution)
Number of subjects: 100
Study 25358078 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mcg of sublingual misoprostol
Number of subjects: 200
Study 25358078 — intervention group
Group type: COMPARATOR
Intervention: 25 mcg of vaginal misoprostol
Number of subjects: 200
Study 23435397 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiosal (NaCl + chitosan 3%)
Number of subjects: 40
Study 23435397 — intervention group
Group type: COMPARATOR
Intervention: NaCl
Number of subjects: 40
Study 21375093 — intervention group
Group type: EXPERIMENTAL
Intervention: Subinguinal technique (5 ml of 1% mepivacaine)
Number of subjects: 106
Study 21375093 — intervention group
Group type: COMPARATOR
Intervention: Nerve-targeting technique (5 ml of 1% mepivacaine)
Number of subjects: 106
Study 19690428 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at a dose of 0.066 mg/kg body weight per day
Number of subjects: 135
Study 17313535 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia multimedia intervention
Number of subjects: 60
Study 17313535 — intervention group
Group type: COMPARATOR
Intervention: One-on-one patient education of routine nursing guide and pain management with pamphlet (Control)
Number of subjects: 60
Study 15278758 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cc of 1% lignocaine + 40 mg of methylprednisolone for the first and second injections
Number of subjects: 48
Study 15278758 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cc of 1% lignocaine + 40 mg of methylprednisolone for the first injection and only 10 cc of 1% lignocaine for the second injection
Number of subjects: 48
Study 15278758 — intervention group
Group type: COMPARATOR
Intervention: only 10 cc of 1% lignocaine for the first and second injections
Number of subjects: 48
Study 11205135 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional imaging (PET and SPECT)
Number of subjects: 0
Study 11205135 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐dopa PET findings in transplantation trials
Number of subjects: 0
Study 9011442 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Number of subjects: 54
Study 9011442 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 54
Study 1600826 — intervention group
Group type: EXPERIMENTAL
Intervention: Alleged 'fast' team
Number of subjects: 128
Study 1600826 — intervention group
Group type: COMPARATOR
Intervention: Alleged 'slow' team
Number of subjects: 128
Study 1600826 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year-old children
Number of subjects: 128
Study 1600826 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year-old children
Number of subjects: 128
Study 1600826 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences
Number of subjects: 128
Study 6385228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular indoprofen
Number of subjects: 0
Study 6385228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31961396 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic Acid added to maximally tolerated statins
Number of subjects: 0
Study 31961396 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to maximally tolerated statins
Number of subjects: 0
Study 30431393 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory‐based Patient portal e‐Learning Program (T‐PeP)
Number of subjects: 272
Study 30431393 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 272
Study 28190797 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 min physical exercise (PE) at school daily
Number of subjects: 445
Study 28190797 — intervention group
Group type: COMPARATOR
Intervention: 2 units of 45-min PE weekly (control group)
Number of subjects: 445
Study 27557301 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused ultrasound thalamotomy
Number of subjects: 76
Study 27557301 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 76
Study 25085230 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncovered metallic stents (n=20)
Number of subjects: 40
Study 25085230 — intervention group
Group type: COMPARATOR
Intervention: Covered metallic stents (n=20)
Number of subjects: 40
Study 22875557 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus conventional care
Number of subjects: 274
Study 22875557 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy plus conventional care
Number of subjects: 274
Study 22875557 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus physiotherapy plus conventional care
Number of subjects: 274
Study 19768295 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Breathing Exercises (DBE)
Number of subjects: 36
Study 19768295 — intervention group
Group type: COMPARATOR
Intervention: Incentive Spirometry (IS)
Number of subjects: 36
Study 17341589 — intervention group
Group type: EXPERIMENTAL
Intervention: Skins compression garment
Number of subjects: 10
Study 17341589 — intervention group
Group type: EXPERIMENTAL
Intervention: Adidas compression garment
Number of subjects: 10
Study 17341589 — intervention group
Group type: EXPERIMENTAL
Intervention: Under Armour compression garment
Number of subjects: 10
Study 17341589 — intervention group
Group type: COMPARATOR
Intervention: Control (no compression garment)
Number of subjects: 10
Study 15807174 — intervention group
Group type: EXPERIMENTAL
Intervention: INF-alpha (5MU 3x per week during 4-6 months)
Number of subjects: 103
Study 15807174 — intervention group
Group type: COMPARATOR
Intervention: lamivudine (100mg per day during 1-4 years)
Number of subjects: 103
Study 11232683 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided celiac plexus block with 10 cc bupivacaine (0.25%) and 3 cc (40 mg) triamcinolone injected on each side of the celiac plexus.
Number of subjects: 90
Study 11232683 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided celiac plexus block
Number of subjects: 90
Study 9648699 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ppm chlorine in filtered air
Number of subjects: 16
Study 9648699 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 16
Study 8270989 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide at 20, 25, or 30 mg/m2/d infused continuously for 14 days (336 hours) with a 10-mg/m2 bolus and cisplatin 30 mg/m2 on chemotherapy days 1, 2, and 3
Number of subjects: 30
Study 8270989 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide at maximum-tolerated dose (MTD) of 25 mg/m2/d
Number of subjects: 30
Study 8270989 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide with Css greater than 1 microgram/mL
Number of subjects: 30
Study 2488361 — intervention group
Group type: EXPERIMENTAL
Intervention: Y connector disinfectant system (Amuchina, Italy)
Number of subjects: 124
Study 2488361 — intervention group
Group type: COMPARATOR
Intervention: Standard systems (Baxter Systems II & III)
Number of subjects: 124
Study 4741606 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis
Number of subjects: 22
Study 4741606 — intervention group
Group type: COMPARATOR
Intervention: Control (no digitalis)
Number of subjects: 22
Study 28864147 — intervention group
Group type: EXPERIMENTAL
Intervention: BMP‐2/hydroxyapatite
Number of subjects: 20
Study 28864147 — intervention group
Group type: COMPARATOR
Intervention: BDX
Number of subjects: 20
Study 25742538 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleep quality
Number of subjects: 710
Study 25742538 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal sleep duration
Number of subjects: 710
Study 25742538 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower work sitting time
Number of subjects: 710
Study 25742538 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging in three risky lifestyle behaviors
Number of subjects: 710
Study 23270495 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-visit asthma service
Number of subjects: 570
Study 23270495 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-visit asthma service
Number of subjects: 570
Study 21530036 — intervention group
Group type: EXPERIMENTAL
Intervention: DOPPS Practice Monitor (DPM)
Number of subjects: 145
Study 20088174 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids
Number of subjects: 80
Study 20088174 — intervention group
Group type: COMPARATOR
Intervention: No antenatal corticosteroids (Control)
Number of subjects: 80
Study 16720886 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 36
Study 15547161 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 9193
Study 10959912 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human deoxyribonuclease (rhDNase)
Number of subjects: 0
Study 10959912 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 9104564 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural human interferon-alpha (nHuIFN alpha) 50 units
Number of subjects: 32
Study 9104564 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural human interferon-alpha (nHuIFN alpha) 150 units
Number of subjects: 32
Study 9104564 — intervention group
Group type: COMPARATOR
Intervention: Natural human interferon-alpha (nHuIFN alpha) placebo
Number of subjects: 32
Study 9104564 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural human interferon-alpha (nHuIFN alpha) 450 units
Number of subjects: 32
Study 9104564 — intervention group
Group type: COMPARATOR
Intervention: Control horses
Number of subjects: 32
Study 1301491 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 150
Study 1301491 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen
Number of subjects: 150
Study 1301491 — intervention group
Group type: COMPARATOR
Intervention: Sodium Diclofenac
Number of subjects: 150
Study 3895034 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride
Number of subjects: 9
Study 3895034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 28480692 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage (MLD) for 30 minutes
Number of subjects: 30
Study 28480692 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Cryotherapy (CRY) for 30 minutes
Number of subjects: 30
Study 28480692 — intervention group
Group type: COMPARATOR
Intervention: Rest (RST) for 30 minutes
Number of subjects: 30
Study 28112691 — intervention group
Group type: EXPERIMENTAL
Intervention: L3‐based probiotic formula (iNatal®)
Number of subjects: 127
Study 28112691 — intervention group
Group type: COMPARATOR
Intervention: Control group (279 pregnant women in 2015 and 892 pregnant women in 2013 and 2014)
Number of subjects: 127
Study 24742300 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face guidance strategy (4 contacts)
Number of subjects: 12
Study 24742300 — intervention group
Group type: EXPERIMENTAL
Intervention: E-guidance strategy (13 contacts)
Number of subjects: 12
Study 23292287 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 88
Study 23292287 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone + Resistance training (RT)
Number of subjects: 88
Study 23292287 — intervention group
Group type: COMPARATOR
Intervention: No Resistance training (RT)
Number of subjects: 88
Study 23292287 — intervention group
Group type: COMPARATOR
Intervention: Placebo + No Resistance training (RT)
Number of subjects: 88
Study 20620624 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractal analysis of airway collapsibility
Number of subjects: 42
Study 20620624 — intervention group
Group type: COMPARATOR
Intervention: Control group (17 control subjects)
Number of subjects: 42
Study 19140644 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive working memory practice on a spatial working memory task for 45 days, approximately 15 minutes per day.
Number of subjects: 2
Study 19140644 — intervention group
Group type: COMPARATOR
Intervention: No intervention (no-contact control groups).
Number of subjects: 2
Study 16493451 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (E)
Number of subjects: 16
Study 16493451 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 16
Study 14648264 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.23 mJ/mm(2) energy flux density
Number of subjects: 80
Study 14648264 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.42 mJ/mm(2) energy flux density
Number of subjects: 80
Study 10433587 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (300 mg weekly) + Primaquine (30 mg daily)
Number of subjects: 151
Study 10433587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 7723545 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 109
Study 7723545 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 109
Study 2200299 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 20 mg pretreatment, followed by induction with propofol plus saline 2 ml
Number of subjects: 103
Study 2200299 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 40 mg pretreatment, followed by induction with propofol plus saline 2 ml
Number of subjects: 103
Study 2200299 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline pretreatment, followed by induction with propofol plus lignocaine 20 mg
Number of subjects: 103
Study 2200299 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline pretreatment, followed by induction with propofol plus lignocaine 40 mg
Number of subjects: 103
Study 2200299 — intervention group
Group type: COMPARATOR
Intervention: Saline pretreatment, followed by induction with propofol plus saline 2 ml
Number of subjects: 103
Study 7389253 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg indacrinone alone
Number of subjects: 12
Study 7389253 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg indacrinone + 2.5 mg amiloride
Number of subjects: 12
Study 7389253 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg indacrinone + 5 mg amiloride
Number of subjects: 12
Study 7389253 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg indacrinone
Number of subjects: 12
Study 30883904 — intervention group
Group type: EXPERIMENTAL
Intervention: Late evening snacks (LES)
Number of subjects: 341